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Abstract
Inﬂammatory bowel diseases (IBD), composed mainly of Crohn’s disease (CD) and ulcerative colitis (UC), are strongly
implicated in the development of intestinal inﬂammation lesions. Its exact etiology and pathogenesis are still
undetermined. Recently accumulating evidence supports that group 3 innate lymphoid cells (ILC3) are responsible for
gastrointestinal mucosal homeostasis through moderate generation of IL-22, IL-17, and GM-CSF in the physiological
state. ILC3 contribute to the progression and aggravation of IBD while both IL-22 and IL-17, along with IFN-γ, are
overexpressed by the dysregulation of NCR− ILC3 or NCR+ ILC3 function and the bias of NCR+ ILC3 towards ILC1 as
well as regulatory ILC dysfunction in the pathological state. Herein, we feature the group 3 innate lymphoid cells’
development, biological function, maintenance of gut homeostasis, mediation of IBD occurrence, and potential
application to IBD therapy.
Facts
● Group 3 innate lymphoid cells (ILC3) are
responsible for gastrointestinal mucosal homeostasis
through moderate generation of IL-22, IL-17 and
GM-CSF in the physiological state.
● ILC3 contribute to the progression and aggravation
of inﬂammatory bowel diseases by the dysregulation
of NCR− ILC3 or NCR+ ILC3 function and the bias
of NCR+ ILC3 towards ILC1 under the stimulation
of IL-12 generated by CD14+ dendritic cells as well
as regulatory ILC dysfunction in the pathological
state.
● The dysregulation of ILC3 results in overexpressions
of inﬂammatory cytokines IL-22, IL-17 and IFN-γ, in
which IL-17 can recruit neutrophil cells to disrupt E-
cadherin and junctional adhesion molecule-like
molecule (JAML), leading to the enhancement of
epithelial permeability.
● The ILC3 to ILC1 plasticity is reversible in the
presence of IL-23, IL-1β and retinoic acid produced
by CD14− dendritic cells.
Open questions
● What is an exact mechanistic process of the ILC3
dysregulation?
● Whether does the ILC3 dysregulation directly
impact ILCreg?
● How to reverse the ILCreg dysfunction and control
the level of CD14 DC?
● Why do the antibodies against human IL-17A or
IFN-γ not show signiﬁcant efﬁcacy in the treatment
of patients with Crohn’s disease?
Introduction
Inﬂammatory bowel diseases (IBD) display non-
speciﬁc and chronic inﬂammatory lesions occurring in
the intestinal mucosa and submucosa, represented by
ulcerative colitis (UC) and Crohn’s disease (CD) that are
considered distinct entities1. Although inherited
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tendency, environmental factors, microbial infection
and inappropriate immune responses are, up to now,
considered to be relevant, detailed etiology and pathol-
ogy of the diseases are still obscure, and the existing
remedies are not satisfactory. Moreover, the risk of
other chronic diseases or even colorectal cancer (CRC)
is dramatically increased in patients suffering from IBD.
Studies indicate that chronic inﬂammation is a
leading factor that converts low and high-grade dys-
plasia into CRC, and about 10–15% of the CRC patients
die from IBD2.
Although patients with CD and UC have some similar
pathological alteration, clinical symptoms and signs, there
are still some differences between them. CD can intrude
upon one or more regions of the intestinal mucosa and
submucosa, but the terminal ileum and colon are mainly
implicated. In contrast, UC has a signiﬁcant impact on the
mucosal layer of the colon or rectum with enduring
inﬂammation and ulcers3. Studies have shown that CD is
mediated by a Th1 response. The highly expressed-tumor
necrosis factor (TNF), interferon-γ (IFN-γ) and
interleukin-17A (IL-17A) were found in CD4+ T cells
separated from inﬂammatory mucosal areas. Conversely,
UC is mediated by a Th2 immune response as IL-4, IL-5,
and IL-13 are highly secreted in inﬂamed tissue4.
Genome-wide associated studies and meta-analyses have
identiﬁed 200 loci related to both CD and UC5,6, showing
that most of the identiﬁed genes are associated with other
autoimmune diseases, such as psoriasis7. Interestingly,
approximately 70% of IBD-related genes are identical
between CD and UC, while only 23 and 30 loci are spe-
ciﬁcally related to the sensitivity to UC and CD, respec-
tively5,8. These susceptible genes are mainly linked to the
host immune system, including adaptive and innate
immune responses to protect epithelial tissue from
mycobacteria and autophagy9. In recent years, innate
immune cells (ILC) and their interaction with inﬂamma-
tory bowel diseases have attracted broad attention. Here,
we focus on mechanistic processes of ILC3 action in
development of IBD.
Innate lymphoid cells
ILC develop from common lymphoid progenitor cells
(CLP) and show resemblance to adaptive lymphocytes in
morphology. Dissimilarly, ILC have no rearranged
antigen-speciﬁc receptors but CD127 (IL-7Rα) is enriched
on their surface10. They can be divided into three groups
on the basis of expression of transcriptional factors and
cytokines11. Group 1 ILC (ILC1) can secrete the Th1-like
cytokine interferon-γ (IFN-γ) under the stimulation of IL-
12, IL-15, and IL-18 in the presence of transcriptional
factor T-bet12,13. Group 2 ILC (ILC2) can generate Th2-
like cytokines IL-5 and IL-13 under the stimulation of IL-
25 and thymic stromal lymphopoietin (TSLP) in the
presence of transcriptional factors RoRα and GATA314.
Group 3 ILC (ILC3) produce Th17- and Th22-like cyto-
kines IL-22, IL-17, and a granulocyte macrophage-colony
stimulating factor (GM-CSF) under the stimulation of IL-
23 and/or IL-1β in the presence of the RORγt and aryl
hydrocarbon receptor (AHR)15. A novel recognized subset
is regulatory ILC that secrete IL10 and TGF-β under the
stimulation of IL-2 in the presence of transcriptional
factors Id3 and sox416. These classiﬁcation features look
similar to those of CD4+ T helper cell subsets (Fig. 1).
Recently, ILC have increasingly been considered as a key
moderator of tissue homeostasis and inﬂammation via
releasing cytokines. They have been known to exhibit
protective responses against microorganisms in lymphoid
tissue formation and in tissue remodeling after damage17.
Analogous to T and B cells, ILC are developed from
CLP. In the presence of nuclear factor interleukin-3 and
inhibitor of DNA-binding 2 (Id2), CLP deviate into
restricted common helper-like innate lymphoid pro-
genitor cells (CHILP). Afterwards, downstream precursor
cells (ILCP) of ILC express transcription factor PLZF and
can give rise to the ILC1, ILC2 and ILC3 subsets18,19.
Accumulating evidence shows that RORγt (encoded by
Rorc) drives differentiation of ILC3 from their precursor
ILCP20. The common cytokine receptor γ-chain (γc) is
essential for the maturation of ILC in mice, constituting
the components of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-
2121. IL-15 is an indispensable regulator for the devel-
opment and differentiation of ILC1 and natural killer
(NK) cells. In contrast, ILC2 and ILC3 are dependent
on IL-7 for development. Knocking out IL-7 or IL-7Rα
will result in a greatly reduced number of ILC2 and
ILC322. However, the precise differentiation and
regulatory mechanisms of ILC in humans and mice
remain elusive.
Group 1 ILC comprise of NK cells and ILC1, they are
primarily involved in eliminating viruses and intracellular
pathogens. Both NK cells and ILC1 secrete IFN-γ and
depend on the transcriptional factor T-bet. NK cells
express transcriptional factor Eomesodermin (Eomes),
which is a key factor discriminating them from ILC123.
They express Nkp46, NK1.1 and CD90 in mice, but CD56,
CD16 and CD94 in humans24. Apart from NK cells, ILC1
may be further categorized to two subsets of Group 1 ILC,
lamina propria ILC1 and intraepithelial ILC1 (iILC1)
(Table 1). In mice, lamina propria ILC1 produce CD127,
Nkp46, T-bet and CD161, and iILC1 yield CD103, CD160,
and NK1.125. In humans, lamina propria ILC1 generate
CD127 and CD161, but not NKp44, CD56 and c-kit. In
contrast, iILC1 express CD56, CD103, CD94, CD160 and
Nkp44, but lack CD12725,26. ILC1 are mainly distributed
within the intestinal lamina propria in both mice and
humans, and the proportion of ILC1 is notably increased
in IBD patients27.
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Group 2 ILC were ﬁrst found in fetal gut tissue and later
in skin, adipose tissue, lung, intestinal submucosa and
lymphoid organs. ILC2 enable tissue to repair and defend
against helminth infection28. They express IL7Rα, CD90.2
(Thy1), CD25, CD117, Sca1, KLRG1, ICOS and ST2 in
mice, but CD25, CD90, CD127, CD161, ST2 and CRTH2
in humans29.
Group 3 ILC are a heterogeneous group, which can be
divided into three subpopulations on the basis of their
function during embryogenesis and their cell-surface
expression of the natural cytotoxicity receptor NKp4630.
Group 3 ILC are characterized by expressing transcription
factors T-bet and RORγt and surface marker CD117
(c-kit)31. Lymphoid tissue inducer (LTi) cells were the
earliest discovered ILC3, which facilitate the formation of
lymph nodes and Peyer’s patches32. In mice, LTi cells
express CD117, CD45, CCR6, CD4 and CD127, whereas
human LTi cells show resemblance to mouse LTi cells,
but do not produce CD433. LTi cells assist the formation
of lymphoid organs in response to TNF-α and
Fig. 1 Characteristic comparison of ILCs with Th cells. According to different cellular phenotypes, transcriptional factors and functional factors,
T helper (Th) cells can be classiﬁed into Th1, Th2, Th17, Th22, Treg and so on. By contrast, ILCs can be divided into three groups ILC1, ILC2, ILC3 and
ILCreg
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lymphotoxin-β stimulation during embryogenesis. Post-
natally, they can also produce IL-17A and IL-22 to defend
the gastrointestinal tract against pathogens34. ILC3 exist
mainly in the intestinal mucosal tissue, playing an
important role in mucosal homeostasis and inﬂammatory
responses. In addition to LTi cells, human ILC3 can also
be subdivided into NCR+ ILC3 and NCR− ILC3 in light of
their expressing the natural cytotoxicity receptors NKp46,
NKp44 and NKp3035. NCR+ ILC3 account for about 70%
of the entire intestinal tract’s ILC. By contrast, NCR−
ILC3 are only around 15%12,36. In line with expressing
chemokine CCR6, ILC3 can fall into CCR6+ LTi and
CCR6− ILC3 lineage30,37. NKp44 expresses on CCR6−
ILC3 in humans, but instead NKp46 in mice, which
causes NCR− ILC3 to eventually develop into NCR+ ILC3
in the presence of IL-1β plus IL-23 in vitro26,38. In mice,
NCR+ ILC3 generate CD117, CD127 and Nkp46, but
human NCR+ ILC3 instead highly express Nkp44 along-
side a low level of Nkp46. Mouse NCR− ILC3 are identical
to human NCR− ILC3 except that CD117 appears on
Table 1 Characteristics of innate lymphoid cells in mice and human
ILC Group Phenotype Localization Disease Reference
mouse Human
Group1 ILC
NK Cell Lin−, Eomes+,
NK1.1+,NKP46+,
T-bet+, CD90+,
CD127−
Lin−, CD127−, CD117−,
CD25+,CD16+,
CD56+, CD94+,
CD161+
Spleen
Lymph node
Crohn’s disease 23,24,95
Intraepithelial ILC1 Lin-, NK1.1+,
CD103+,CD160+,
CD127−
Lin−, Nkp44+,
CD103+,CD127−,
CD160+, CD94+
Intestine lamina propria,
Intestine epithelial layer
Crohn’s disease
Colitis
25,26,28
Lamina propria ILC1 Lin−, Nkp46+, Tbet+,
CD127+,CD161+
Lin−, CD56−, C-kit−,
Nkp44−, CD127+,
CD161+
Intestine, lamina propria Crohn’s disease
Colitis
12,25–28
Group2 ILC
ILC2 Lin−, CD25+, SCA1+,
ICOS+, ST2+, Thy1+,
IL7Rα+, CD117+
Lin−, CD161+, ST2+,
CRTH2+,CD127+,
NK1.1+,Nkp44−,
CD25+,CD117+,
CD90+
Skin, lung, adipose tissue,
spleen, MLN
Asthma
Allergy
Colitis
14,28,29,96
Group3 ILC
LTi Lin−, CCR6+, CD4+,
CD3−, CD45+,CD90+,
CD117+, CD127+,
IL-23R+
Lin−, CCR6+, CD45+,
CD90+,CD117+,
CD127+, CD4−, CD56−
Lymph node, Peyer’s patches Autoimmune
disease
28,32,33
NCR− ILC3 Lin−, Nkp46−, CD25+,
D90+,CD127+,
CD117−
Lin−, CCR6+, Nkp44−,
CD25+, CD117+,
CD127+, CD161+
Epithelial tissues, Intestine,
Skin
Crohn’s disease
colitis
28,38,41,97
NCR+ ILC3 Lin−, Nkp46+,
CD117+,
CD127+,CD90+
Lin−, CCR6+, Nkp44+,
KP30+, CD117+,
CD127+, CD161+
Epithelial tissues, Intestine
Skin
Colitis 24,28,39–41
Group4 ILC
ILCregs Lin−, CD45+, CD25+,
D90+, CD127+,
IL10+, CD4−, Foxp3−
Lin−, CD45+, CD25+,
CD90+, CD127+,
IL10+,CD4−, Foxp3−
Intestine Colitis 16
Lin− lineage marker-negative, CRTH2 chemoattractant receptor-homologous molecule expressed on TH2 cells, ICOS inducible T cell co-stimulator, CCR CC-chemokine
receptor, SCA-1 stem cells antigen-1, NCR natural cytotoxicity receptor, IL7Rα CD127, MLN mesenteric lymph nodes
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human NCR− ILC3 and not on mouse NCR− ILC339.
NCR+ ILC3 primarily express IL22, but less IL-17. In
contrast, NCR− ILC3 predominantly produce IL-17, but a
lesser amount of IL2240. In vitro, NCR− ILC3 can switch
to NCR+ ILC3 in the presence of IL-1β and IL-2341.
RORγt and AHR are necessary for the development of
CCR6+ and CCR6– ILC3. A knockout of RORγt com-
pletely halts ILC3 formation, rather than that of ILC1 or
ILC2. In addition, AHR highly expresses in ILC3 and is
essential for maintaining ILC342. However, the underlying
mechanisms of ILC3 development and maintenance are
not still elucidated.
Recently, Wang et al. identiﬁed a novel subset of ILC,
named regulatory ILC (ILCreg). They found an IL-10-
producing subset of innate cells that mainly presents in
the intestinal tract and expresses various phenotypic ILC
markers, such as CD25, IL-2R, Sca-1 and CD90. Fur-
thermore, these cells express neither CD4 nor FoxP3,
signature markers of CD4+ regulatory T cells (Treg),
which makes ILCreg distinct from Treg. ILCreg are
derived from CHILP instead of ILCP and highly express
the transcriptional factors Id3 and Sox4, lacking other
transcriptional factors that are essential for the develop-
ment of ILC, such as Nﬁl3, Ror, Gata3 and AHR. ILCreg
play an important role in innate immune responses,
relieving intestine inﬂammation through generating IL-10
and TGF-β16,43. Interestingly, they resemble lymphoid
cells morphologically with a high nuclear to cytoplasmic
ratio. In addition, another regulatory subset, CD56+CD3−
ILC were recently recognized to display regulatory roles in
human and mice. These cells express NK cell- and ILC-
associated molecules, such as CD56, CD94, NCR3
(NKP30) and NCR1 (NKP46). Like ILCreg, the
CD56+CD3− ILC do not express Foxp3, but highly yield
EOMES, TBX21, GATA3, RORA, and AhR. Dissimilarly,
the CD56+CD3− ILC may originate from NK cells, gen-
erate IL-22 but not IL10, and inhibit tumor-inﬁltrating
lymphocytes43,44.
ILC3 in the maintenance of gut homeostasis
ILC3 are implicated in gastrointestinal immune
responses. They protect the intestinal mucosa from
infections of various pathogens to maintain intestinal
homeostasis in the steady state. This protective effect is
mainly realized through the secretion of IL22, IL-17 and
GM-CSF, triggering epithelial cells to produce anti-
microbial peptides (AMPs), such as RegIIIβ and RegIIIγ
that kill pathogens45, regulating T cell responses to
commensal bacteria through the expression of a MHC-II
molecule46,47, supporting the tolerance function of
intestinal dendritic cells (DC) via GM-CSF secretion, and
adjusting epithelial glycosylation48.
IL-22, a member of the IL-10 family, displays a homo-
logous secondary structure, binding to its heterodimeric
receptors IL-22R1 and IL-10R2 on the surface of epithelial
cells. IL-22 signaling induces the generation of mucin and
pro-inﬂammation molecules. It also facilitates tissue
repair through boosting epithelial cell proliferation and
survival49. Besides, IL22 is able to promote the production
of nucleotide oligomerization domain-containing pro-
tein2 (NOD2), which is related to the innate immune
response. The activation of the NOD2 signaling can
promote the secretion of mucin and AMPs protecting
intestinal epithelial cells from invading bacteria50.
Therefore, IL-22 contributes to preventing bacterial
infections, relieving intestinal inﬂammation and restoring
tissue injury during hepatitis or colitis (Fig. 2a)51. In a
mouse model of graft-vs.-host disease, ILC3-derived IL-22
can activate intestinal stem cells to impede tissue
damage52. In addition, ILC3 triggers intestinal epithelial
fucosyltransferase 2 (Fut2) expression and fucosylation in
mice through secreting IL-22 and lymphotoxin in a
commensal bacteria-dependent or independent manner.
Fut2 regulating H antigen expression in gastrointestinal
mucosa has been reported to mediate the fucosylation of
intestinal epithelial cells53.
Except for IL-22, the NCR− ILC3 can also generate IL-
17. Increasing evidence indicates that it can stimulate
epithelial and endothelial cells to secrete chemokines and
other chemoattractants, and also inﬂuence the inﬂam-
matory immune response by recruiting proinﬂammatory
neutrophils54. The neutrophils play a protective role in
supporting epithelial barriers and maintaining intestinal
homeostasis through producing ROS and α-defensin
(Fig. 2a). Recent researches demonstrate that γδ T cells
are the source of early and protective IL-17 after an acute
intestinal injury and IL-17 can maintain and protect
epithelial barriers in the intestinal mucosa by regulating
the tight junction protein in an independent-IL-23
manner55.
On the other hand, the interaction between macro-
phages and ILC3 can maintain gut homeostasis via GM-
CSF. RORγt+ ILC3 are an important source of GM-CSF
in the physiological state that relies on microbial signals
and IL-1β production by macrophages48. IL-1β promotes
ILC3 to produce GM-CSF, which initiates the release of
retinoic acid (RA) and IL-10 by DC and macrophages in
the mucosa to facilitate Treg proliferation48. GM-CSF
mediates mononuclear phagocytes (MNP) that are com-
posed of DC and macrophages to keep intestinal Treg
balance (Fig. 2a). Deleting GM-CSF can alter the function
of mononuclear phagocytes, leading to reduced Treg
numbers and broken oral tolerance. CX3CR1+ MNP can
produce IL-23 and IL-1β, dependent upon
MyD88 signaling56. MNP detect microbial signals and
present extracellular antigens to T lymphocytes.
In mice, ILC3 exert a crucial role in gastrointestinal
mucosa immunity by directly promoting epithelial cell
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proliferation, inducing production of anti-inﬂammatory
cytokines and antimicrobial peptides, preventing dis-
semination of intestinal bacteria, and suppressing CD4+
T-cell responses. Thus, we speculate that ILC3 might have
similar functions in humans. ILC3 interact with CD4+
T cells in maintaining gut homeostasis and in response to
stimuli from commensal bacteria. In fact, ILC3 can
express MHC-II molecules in humans47. In mice, MHC-
II+ ILC3 may present microbiota-derived antigens to
commensal-speciﬁc CD4+ T cells (Fig. 2a). These
commensal-speciﬁc CD4+ T cells are killed to induce
tolerance to these commensals for lack of the co-
stimulatory molecules CD40, CD80 and CD8646,47.
However, IL-1β stimulates NCR− ILC3 to produce CD80
and CD86 in mouse spleen57. This difference may be due
to the different micro-environments in various tissues.
MHC-II-producing ILC3 are found to regulate intestinal
homeostasis by inducing apoptotic cell death-activated
commensal bacteria-speciﬁc T cells47. It has been revealed
that patients with pediatric Crohn’s disease have lower
levels of MHC-II+ ILC3 than individuals without this
condition47. Hence, ILC3 regulate intestinal homeostasis
by a cytokine-dependent pathway and cell surface recep-
tor regulatory mechanisms.
Strikingly, newly found ILCreg participate con-
comitantly in maintenance of gut homeostasis via
secreting IL-10 and TGF-β. ILCreg noticeably inhibit the
production of IFN-γ and IL-17A by ILC1 and NCR−
ILC3, respectively, to reduce their pro-inﬂammatory
activity, while IL-22 production by NCR+ ILC3 is unaf-
fected by ILCreg. In addition to IL-10, ILCreg can pro-
duce TGF-β1 in an autocrine manner, which supports the
maintenance and proliferation of ILCreg. Therefore, if the
inhibitory action of ILCreg is not enough to offset detri-
mental impacts produced by ILC1 and over-activated
NCR− ILC3 or NCR+ ILC3, inﬂamed intestinal lesions
occur or are exacerbated.
ILC3 in inﬂammatory bowel diseases
Using Rag2−/−Tbx21−/− mice (TRUC mice), a mouse
model of UC, Ermann et al. found that IL-23 triggered
secretion of IL-17A by NCR− ILC3 to play a signiﬁcant
role in the development of colitis58. Recent studies indi-
cate that dysregulation of the IL-23/IL-17 axis is involved
Fig. 2 ILC3 in maintenance of gut homeostasis and occurrence of inﬂammatory bowel diseases. a Macrophages are stimulated by bacteria,
releasing IL-1β. IL-1β engages an IL-1 receptor on ILC3, promoting IL-22, IL-17 and GM-CSF release. GM-CSF triggers DCs and Macrophages to
generate retinoic acid and IL-10, which in turn promote the formation of Treg cells. IL-22 promotes epithelial barrier integrity and proliferation,
inducing the production of AMPs, REG3γ and mucin. IL-17 can recruit neutrophils and also supports epithelial barrier protection. MHC-II-expressing
ILC3 can inhibit commensal speciﬁc CD4+ T cells. NCR- ILC3 can switch to NCR+ ILC3 with IL-1β plus IL-23 stimulation. b In IBD, the number of the
IL-17-producing NCR− ILC3 has been shown to be increased. IL-17 can recruit neutrophil cells. The neutrophil transmigration can disrupt junction
proteins, such as E-cadherin and JAML, leading to the enhancement of epithelial permeability. The increase of the IFNγ-producing ILC1 cells of
intraepithelial ILC1 and CD127+ ILC1 is accompanied by a large decrease in the number of NCR+ ILC3 cells. NCR+ ILC3 produces excessive IL-22 in
IBD. ILC3 can differentiate into ILC1 under the stimulation of IL-12 produced by CD14+ DCs. This ILC3 to ILC1 plasticity is reversible in the presence of
IL-23, IL-1β and retinoic acid produced by CD14− DCs. The population of the IFNγ-producing ILC1 is increased at the cost of the decreased NCR+
ILC3 cells
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in various genetic susceptibilities in CD and UC patients
due to dysfunction of the innate and adaptive immune
responses59. IL-17 also acts on many types of stromal,
epithelial and myeloid cells to generate a great number of
pro-inﬂammatory cytokines, such as IL-1β, IL-6 and TNF,
and chemokines enlisting neutrophils and macrophages.
Emerging evidence shows that the increased level of
migrating neutrophils can destroy junction proteins, such
as E-cadherin and a junctional adhesion molecule-like
factor, and produce microscopic gaps between epithelial
cells, further impairing the epithelial barrier and exacer-
bating intestinal inﬂammation in IBD60. Moreover, mas-
sive neutrophil transmigration can alter the cellular
expression levels of tight junction proteins, leading to
injury of the epithelial barrier and enhancement of the
epithelial permeability (Fig. 2b)60. In IBD, the number of
CD68+ macrophages is abnormally increased. In the
mucosa and submucosa, the inﬁltrating macrophages are
found to express Toll-like receptors, such as TLR-2, TLR-
4 and TLR-561. However, secukinumab, a speciﬁc anti-
body against human IL-17A, fails to alleviate CD. On the
contrary, it worsens this disease62 though IL-17A has a
protective effect in the intestinal epithelial permeability55,
suggesting that ILC3 do not impulse the pathological
progress of the inﬂamed mucosa directly through IL-17A
secretion.
The inappropriate activation of ILC3 has been proven to
cause intestinal damage through excessive production of
IL-22. This may induce epithelial cells to generate neu-
trophil chemoattractants, leading to accumulation of
neutrophils and tissue destruction (Fig. 2b)63. Uhlig et al
found that NKp46+ ILC3 could induce inﬂammation
through the excessive production of IL-22 and GM-CSF
in the anti-CD40 model of colitis64. Additionally, colonic
ILC3 from UC and CD patients displayed a distinctly
higher expression of IL-22 than in healthy individuals56.
However, IL-22 was reported to have protective effects in
some experimental models of colitis65 and reduced in CD
patients66. In a Th2-mediated chronic colitis model
(TCR□KO mice) representing UC, IL-22 could amelio-
rate intestinal inﬂammation by enhanced mucus pro-
duction. IL-23-responsive IL-22 was also shown to relieve
colon inﬂammation in murine colitis induced with dex-
tran sodium sulfate or Citrobacter Rodentium67 and ILC3-
deﬁcient mice generated scant IL-22 to enhance sensi-
tivity to Citrobacter Rodentium68. Niess et al. also found
that the IL-22-deﬁcient mice were highly susceptible to
intestinal inﬂammation caused by Candidiasis69. Intest-
inal macrophages can accelerate the intestinal inﬂamma-
tion in CD patients through crosstalk with RORγt ILC3 to
increase the production of IL-22. Another report
demonstrates that CD14+ CX3CR1+ mononuclear pha-
gocytes increase the expression of IL-22 in ILC3 through
producing TL1A, IL-23 and IL-1β. DC are also able to
mediate ILC3 to secrete IL-2256. Emphatically, although
CD103+ DC and CD14+ macrophages may aggravate
intestinal inﬂammation in CD patients, they are also able
to facilitate a negative feedback pathway via the produc-
tion of IL-22 by ILC370. Collectively, IL-22 is a double-
edged sword in intestinal inﬂammation and in intestinal
tract protection.
The number of ILC1, especially in the lamina propria, is
greatly increased to about 10–40% of the total ILC in the
inﬂamed intestinal mucosa in CD patients12,26,27 with
enhancing relative severity of the mucosa inﬂammation.
The population of the IFNγ-producing ILC1 is increased
at the cost of decreased NCR+ ILC3 in the inﬂamed
intestine in IBD patients12,26. ILC3 can deviate towards
ILC1 under the stimulation of IL-12 production by
CD14+ DC12, suggesting the imbalance between ILC3 and
ILC1 may result in CD. Bernink and his colleagues
recently revealed that the differentiation of NKp44+ ILC3
to CD127+ ILC1 is reversible, relying on appropriate
assembling of cytokines. For example, ILC1 may deviate
into ILC3 in the presence of IL-23, IL-1β and retinoic acid
produced by CD14− DC12. The differentiation of IL-22-
producing ILC3 into IFNγ-producing ILC1 has been
proven to be highly associated with colitis development in
mice (Fig. 2b). In some inﬂammatory situations, NKp46+
ILC3 down-regulate RORγt to promote T-bet expression,
becoming a source of IFN-γ71. These cells are designated
as ex-RORγt ILC3, participating in innate immune
defense against infection by Salmonella Thyphymurium30.
ILC2 generating IFN-γ and IL-13 have also been found in
the intestinal tissues of CD patients72, suggesting a certain
plasticity between ILC1 and ILC2 in response to IL-12.
Recently, it has been indicated in Rorα-deﬁcient and
Rorαsg/sg/Rag1−/− mouse models that the Rorα-
dependent ILC3, rather than ILC2, function in the
development of intestinal ﬁbrosis, hinting at a potential
therapeutic target for IBD31. Therefore, azathioprine and
inﬂiximab, an immunosuppressant and an antibody spe-
ciﬁc to TNF, respectively, are clinically harnessed to treat
CD patients. A markedly decreased expression of IFN-γ
was indeed observed in the inﬂamed gut mucosa, sug-
gesting that IFN-γ might be a therapeutic option for CD.
Of note, the CD patients treated with Fontolizumab, a
humanized murine anti-IFN-γ antibody, did not show
statistical efﬁcacy in clinical trials although there was an
improvement in clinical symptoms with a signiﬁcant
decrease in C-reactive protein levels73. These results
indicate that IBD is a complicated pathological process
mediated by multiple mechanisms. Single therapeutic
strategy will difﬁcultly operate upon this disease.
In the intestinal samples of patients with IBD, Geremia
et al. found that Lin− CD56−CD127+ ILC accumulated in
the inﬂammatory ileum and colon of CD, but not UC
patients. These cells could express IL17 and IFN-γ to
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respond to IL23 in vitro74. Increased ILC frequencies have
recently been found in patients with primary sclerosing
cholangitis-associated IBD, but not in those with UC75.
Analysis of human tissue samples shows that plasticity
between NCR+ ILC3 and ILC1 subsets is dependent on
the local cytokine environment. The antimicrobial
peptide-secreting-RORgt+NKp44+ ILC3 are trans-
differentiated into ILC1 that produce IFNγ to induce
chronic inﬂammation in the presence of IL-23 and IL-
1276. This process was observed by the addition of IL-2
and IL-12 to culture fetal intestine NKp44+ ILC3. The
combination of IL-2 with IL-12 rapidly caused the loss of
NKp44 and c-kit expression in fetal intestine NKp44+
ILC3 with the acquirement of ILC1 phenotype26. There-
fore, the population of IFNγ-producing ILC1 is increased
at the cost of decreased NCR+ ILC3 cells in the inﬂamed
intestine in IBD patients. Human gut ILC3 express not
only a leukemia inhibitory factor (LIF) that stimulates
proliferation of epithelial cells, but also IL-26 that nega-
tively modulates proliferation of intestinal epithelial cells
and facilitates ILC3 to produce proinﬂammatory TNF and
IL-839. CD14+ DC are source of IL-12 cytokines. They
also secrete IL-22 binding protein that counteracts the
role of IL-2277. These data may reﬂect ILC3 functional
ﬂexibility. In view of the above ﬁndings, Feagan et al.
intravenously administered ustekinumab, a speciﬁc anti-
body to the p40 subunit shared by both interleukin-12 and
interleukin-23, to treat patients with moderate to severe
active CD. Consequently, the clinical remission in the
patients was observed and if the ustekinumab was sub-
cutaneously injected at a dose of 90 mg every 8 weeks or
every 12 weeks, this relief could be maintained78, further
supporting that the CD14+ DC-produced IL12 and the
CD14− DC-produced IL-23 indeed play a crucial role in
the process of conversion of NCR+ ILC3 to ILC1.
Last but not least, a relationship of gut microbiota with
IBD is concerned as well. Alteration of gut microbiota is
closely linked to initiation or progression of IBD, but it is
indistinct whether gut microbiota is a primary or sec-
ondary event. It is well known that a mutually beneﬁcial
symbiotic relationship between humans and gut micro-
biota is necessary for maintaining gastrointestinal home-
ostasis. However, intestinal ﬂora is dynamically changing
with age and environmental alteration79. Its composition
and function is affected by various environmental factors,
such as birth, diet, stress, antibiotic treatment and so on80.
Among such environmental factors, diet appears to be an
important modulator of intestinal immunity with direct or
indirect effects on the structure and activity of the
intestinal ﬂora81,82. Short chain fatty acids (SCFA) are
generated by the gut microbiota and regulated by patterns
of food intake. Emerging evidence show that the effect of
SCFA and their metabolite on IBD is mainly modulated
by innate immunity responses and adaptive immune
responses83. For example, Aryl hydrocarbon receptor
(AHR) is present in intestinal epithelium, macrophages, B
cells, T cells and dendritic cells. Kynurenine, an endo-
genous AHR ligand, is derivative of essential amino acid
tryptophan, and many dietary ligands of AHR, including
galangin, genystein, chrysin, apigenin and quercetin,
belong to natural ﬂavonoids residing in fruits and vege-
tables84. It has been proved that the diet-derived AHR
ligands can mediate IL-22 expression to induce the gen-
eration of AMPs and mucin, thus protecting intestinal
mucosa from pathogen invasion and maintaining barrier
integrity85. On the contrary, the expression of innate-
driven IL-22 was reduced for lack of AHR in ILC3, leading
to the expansion of segmented ﬁlamentous bacteria with
occurrence of colitis86. Collectively, these studies
demonstrate that AHR acts as a necessary sensor for
environmental factors and human lifestyle factors, such as
diet, and is also essential for maintenance of NKp46+
ILC3 function.
Overall, ILC3 relies primarily on moderate production
of IL-22, GM-CSF and IL-17 secreted by NCR+ ILC3 and
NCR− ILC3, respectively, to mediate the defense to
pathogens. IL-1β and IL-23 with RA are released by
macrophages and DCs under stimulation of microbe,
which might keep the conversion of ILC1 to NCR+
ILC3 subset. The moderate production of IL-22 conduces
to epithelial barrier integrity and proliferation, stimulating
secretion of AMPs, REG3γ and mucin, and enhancing
epithelial fucosylation. Alternatively, IL-17 can recruit
neutrophil cells to support the protection of epithelial
barrier by expression of ROS and α-defensin. GM-CSF
triggers DCs and Macrophages to generate retinoic acid
and IL-10, which facilitate the formation of oral tolerance.
In addition, MHC-II-expressing ILC3 can inhibit com-
mensal speciﬁc CD4+ T cells. If intestinal epithelia are
continuously invaded by massive pathogens, IL-22 or IL-
17 is overexpressed by NCR+ ILC3 or NCR− ILC3. They
recruit more neutrophil cells to excessively secrete pro-
inﬂammatory factors, incurring the swift enhancement of
epithelial cell permeability. Importantly, NCR+ ILC3 can
deviate towards ILC1 under the stimulation of IL-12
generated by CD14+ or CD130+ DC. The IFNγ-
producing intraepithelial ILC1 and CD127+ ILC1 are
largely increased. The excessive production of IFNγ will
result in epithelial cell damage, eventually exacerbating
the inﬂammatory reaction.
Therapeutic potential of ILC in inﬂammatory
bowel diseases
As well known, IBD is a chronic non-speciﬁc inﬂam-
matory disease without effective drug treatment. At pre-
sent, medical therapy focuses mainly on usage of anti-
inﬂammatory drugs, such as thiopurines, mercaptopurine,
5-aminosalicylic acid and methotrexate (Table 2). In
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general, anti-inﬂammatory drugs are the ﬁrst clinical
practice in the process of IBD treatment to attenuate
intestinal inﬂammation, but cause various adverse effects.
Moreover, many patients with IBD do not procure clinical
remission with the treatment of mesalazine, immuno-
suppressant and monoclonal antibodies against inﬂam-
matory cytokine TNF87. Thus, it is urgent to identify and
develop novel drugs with high efﬁciency and low toxicity.
Over the past 10 years, ILC have gradually been
recognized to be closely related to the pathogenesis of
IBD and are promising to become an emerging ther-
apeutic target. The transcriptional factor RORγt is
indispensable for the development and differentiation of
ILC3. Withers et al. used Rorcﬂox and Id2iΔROR-γt mice
with ILC3 deﬁciency to establish an intestinal inﬂamma-
tion model through infection with Citrobacter rodentium.
They found that the administered inhibitor of RORγt
(GSK805) observably could relieve inﬂammation in mice
by preserving ILC3 and limiting Th17 responses. The
treatment of CD with GSK805 did not alter the propor-
tion of ILC3, but reduced the percentage of pro-
inﬂammatory Th17 and Th22 cells, suggesting that
ROR-γt acts as a therapeutic target for IBD and other
chronic inﬂammatory diseases88. In another aspect, IL-12
Table 2 Pharmacotherapy for IBD
Drug Target Mechanism Reference
Aminosalicylates (5-aminosalicylates,
Sulphasalazine, Olsalazine)
eIF4b, eIF4e (a) Scavenging reactive oxygen species 98,99
(b) Upregulation of endogenous antioxidant systems
(c) Altering faecal bacteria proﬁles and exerting anti-inﬂammatory activities by
inhibition of leukocyte motility
(d) Inhibiting tetrahydrobiopterin biosynthesis and NO formation
(e) Preventing mitochondrial damage by inhibition of phosphatidic acid formation
and phosphatidylethanolamine degradation, and alteration of mitochondrial lipid
composition
(f) Interfering with TNF-α, TGF-β, NF-κB and IL-1
(g) Suppressing the proliferation of human colon cancer cells and by inhibiting
MMP-2 and MMP-9 expression via NF-κB-mediated cell signals and invasiveness
(h) Interacting with the Wnt/β-catenin pathway via inhibition of PP2A and with
the active center of tumor suppressor PPAR-γ
(i) Arresting colon epithelial cells in S-phase by the activation of an ATR-
dependent checkpoint and improving replication ﬁdelity
(j) Down-regulation of expression of endostatin and angiostatin by modulation of
MMP2 and MMP9 via inhibition of TNF-α
Glucocorticoids (Budesonide,
Hydrocortisone, Prednisolone)
undetermined (a) Steroid-activated GR binds to glucocorticoid-responsive elements, resulting in
modulation of antiinﬂammatory transcriptional pathways such as NF-κB, annexin1
and MAPK.
100
(b) GR can decrease the expression of proinﬂammatory genes directly by
protein–protein interactions.
(c) Glucocorticoids ameliorate ER stress in intestinal secretory cells by promoting
correct protein folding and enhancing degradation of misfolded proteins.
Immunomodulators (6-mercaptopurine,
azathioprine, methotrexate)
undetermined (a) Formation of thioguanine nucleotides leads to inhibition of DNA, RNA and
protein synthesis, and induction of cytotoxicity and immunosuppression.
101,102
(b) Inducing T cell apoptosis by blockade of Rac1 activation upon CD28 co-
stimulation and suppressing MEK, NF-κB, and bcl-xL
(c) Methotrexate competitively binds to folic acid in combination with
dihydrofolate reductase, interfering with DNA synthesis and leading to cell death.
(d) Decreasing pro-inﬂammatory cytokine production and induction of
lymphocyte apoptosis
Antibiotics (Flagy, Ciproﬂoxacin,
Cephalosporins)
undetermined (a) Altering composition of intestinal bacteria, reducing harmful bacteria and
promoting the growth of probiotics to reduce inﬂammation
103,104
(b) Reducing bacterial invasion of surrounding tissues in the intestinal lumen, and
bacterial migration and systemic dissemination
Biological agents (Inﬂiximab, Adalimumab,
Etanercept)
TNF-α (a) Neutralizing the biological activity of TNFα by binding to the soluble and
transmembrane forms of TNFα with high afﬁnity, preventing it from binding to
cellular receptors and inducing the lysis of cells
105,106
(b) Restoring the gut barrier, preventing leukocyte inﬁltration in intestinal mucosa
and reducing the expression of β7 and CCR7 in leukocytes, thereby inhibiting
inﬂammation
(c) Incurring apoptosis of T lymphocytes and mononuclear macrophage
eIF4b eukaryotic translation initiation factor 4B, eIF4e eukaryotic translation initiation factor 4E, NO nitric oxide, NF-κB nuclear factor kappa-light-chain-enhancer of
activated B cells, PPAR-γ peroxisome proliferator activated receptor-γ, MMP-2 metalloproteinases 2, PP2A protein phosphatase 2A, GR glucocorticoid receptor, MAPK
mitogen-activated protein kinase, ER endoplasmic reticulum, Rac1 Ras-related C3 botulinum toxin substrate 1, MEK mitogen-activated protein kinase kinase, bcl-xl B-
cell lymphoma-extra large, CCR7 C-C chemokine receptor type 7
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is implicated in playing a key role in ILC2 and ILC3
plasticity. It is a pro-inﬂammatory cytokine generated
primarily by antigen presenting cells in answer to bacterial
infection, and accumulated in the inﬂamed gut mucosa.
Ustekinumab, a human speciﬁc antibody against p40, a
subunit shared by both IL-12 and IL-23, can block IL-12
and IL-23 through binding an IL-12 Rβ1 receptor to
relieve inﬂammation in patients with CD89. It can also
induce and maintain the effects of anti-TNF therapy in
moderate-to-severe CD patients90.
Many clinically used therapeutic agents may affect ILC
differentiation, homeostasis or function. Target cytokine-
cytokine receptors, such as IL-2-IL-2R, IL-12-IL-12R, IL-
23-IL-23R, IL-1-IL-1R, TSLP-TSLPR and IL-6-IL-6R, play
critical roles in the differentiation, function, and main-
tenance of ILCs. Targets 4β7 and MAdCAM-1 are
responsible for the migration of ILCs, and targets TNF-
TNFR and IL-17-IL-17R are implicated in the function of
ILCs91. A developed strategy is to use the cytokines IL-33
or IL-25 to promote an anti-inﬂammatory ILC2 response,
appearing effective in various chronic preclinical models
of inﬂammation92. Another potential therapeutic
approach is to facilitate the transition between the ILC1
and ILC3 subpopulations via the cytokines involved in
ILC1/ILC3 plasticity12. In order to selectively regulate
both protective and pathological ILC responses, some
small molecule inhibitors of transcription factors, such as
GSK80588, and other ILC modulators, including the
vitamin A metabolite retinoic acid and Lipoxin A493, are
being developed. In addition, microbes and diet signals
can greatly affect intestinal ILC94, which may also be an
effective strategy to boost protective ILC responses while
potentially limiting pathologic ILC responses.
Conclusions
The detailed etiology and pathogenesis in IBD remain
confused. However, the accumulating data indicate that
the etiology of chronic intestinal inﬂammation is an
inappropriate immune response to host microorganisms.
Innate and adaptive immune responses may play a key
role in the pathogenesis of IBD. Further evidence strongly
supports that ILC3 maintain micro-environmental
homeostasis of the gastrointestinal mucosa through
moderate production of IL-22, IL-17 and GM-CSF to
protect gut epithelia from microbe invasion in the phy-
siologic state, but also contribute to the evolution and
aggravation of IBD if IL-22 and IL-17 with IFN-γ become
overexpressed due to dysregulation of ILC3 functions and
with their transition towards ILC1 in the pathological
state. Thus, ILC3 appear to be a double-edged sword in
inﬂammatory bowel diseases. Even so, understanding of
ILC3 is still in its infancy and many problems remain
unclear. Thus, uncovering detailed roles of ILC3 in the
various phases of the inﬂammatory immune responses is
vital to elucidating the pathological mechanisms of IBD.
The number of IL-17-producing NCR− ILC3 is markedly
increased in IBD. IL-17 can recruit neutrophil cells to
disrupt E-cadherin and JAML, leading to the enhance-
ment of epithelial permeability. IFNγ-producing ILC1 are
enhanced at the cost of decreased NCR+ ILC3 levels.
ILC3 can differentiate into ILC1 under the stimulation of
IL-12 produced by CD14+ DC. This ILC3 to ILC1 plas-
ticity is reversible in the presence of IL-23, IL-1β and
retinoic acid produced by CD14- DC. Hence, the antibody
ustekinumab was conceived to block both IL-12 and IL-23
through binding to an IL-12Rβ1 receptor, ultimately
relieving the clinical manifestation of IBD. However, other
antibodies against human IL-17A or IFN-γ do not show
signiﬁcant efﬁcacy in the treatment of CD patients, sug-
gesting that the pathogenesis of IBD is highly complicated
and a single therapeutic strategy will have difﬁculty
operating upon this disease.
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